• 6 min read
• Published on 15 November 2025
Listen to article
6:50Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article
Let’s be honest, there’s a palpable sense of panic wafting through the boardrooms of the world’s largest pharmaceutical companies. For years, they’ve been dining out on blockbuster drugs, raking in billions from medicines that have become household names. But the party, it seems, is coming to an abrupt end. The dreaded ‘patent cliff’ is no longer a distant threat on a PowerPoint slide, it’s a fiscal black hole looming just a few years away.
Take Merck, for instance. Its cancer drug, Keytruda, is a modern marvel, pulling in over £20 billion a year. The problem? Its patent starts to crumble in 2028. When that happens, generic drug makers will swarm in like vultures, and that colossal revenue stream could shrivel by 80 percent almost overnight. This isn’t just a headache, it’s a corporate existential crisis. And it explains why they just splashed nearly £7.5 billion on a company called Cidara Therapeutics, a firm whose best ideas are still bubbling away in clinical trials.
So, why on earth would a giant like Merck pay a king's ransom for a company with no finished products? It’s simple, really. Big Pharma has woken up to the fact that its own research labs are often too slow and bureaucratic to plug the impending revenue gaps. Developing a new drug from scratch is a decade-long, billion-pound gamble with absolutely no guarantee of success. It’s a bit like trying to build a Formula 1 car from spare parts in your garage while the championship race is already underway.
Instead, it’s far quicker, and arguably less risky, to simply buy a nearly finished car from a specialist team. That’s what these small biotech firms represent. They’ve done the hard yards, navigated the early clinical trials, and have something tangible. They possess the one thing Big Pharma desperately needs: innovation on a deadline. This has turned the tables completely, creating a seller's market where plucky biotechs with promising late-stage drugs can practically name their price.
For us investors, this frantic scramble creates a fascinating landscape. I see two clear ways to approach this. You could back the hunters, the established giants like Merck or Pfizer. They have deep pockets and a clear motive. A smart acquisition could bolster their pipeline and, in theory, their share price. The risk here is that they might overpay in their desperation, but they are certainly the players with the most power.
Alternatively, you could try to pick the hunted. These are the smaller, innovative biotech firms with the assets everyone wants. If you can spot a likely takeover target before a deal is announced, the returns could be spectacular. Of course, it’s a high-stakes game. For those of us keen to follow this dynamic, keeping an eye on a curated list like the M&A Activity Overview | Pharma Biotech Investments basket could be a rather shrewd move, as it tracks the key players on both sides of the equation.
Before you get carried away, a dose of realism is required. Investing in biotech is not for the faint of heart. For every success story, there are a dozen promising drugs that fail spectacularly in late-stage trials, wiping out shareholder value in a single afternoon. A regulatory body can reject a drug for any number of reasons, and not every innovative company will find a suitor. This is a sector driven by data, hope, and a significant amount of luck. The potential rewards are high, but so are the risks. Never forget that.
View the full Basket:M&A Activity Overview | Pharma Biotech Investments
View the full Basket:M&A Activity Overview | Pharma Biotech Investments
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article